Skip to main content

Stoke Therapeutics, Inc.

STOK
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001623526

In the last 90 days, Stoke Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 197 institutions reported holding it in 13F filings for Q2 2026, worth $2.49B in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Stoke Therapeutics, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of STOK: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders10697−9
Shares38.4M20.2M−18.2M (−47.4%)
Value$1.49B$680.3M−$812.0M (−54.4%)

New holders (11)

Institutions that held Stoke Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to STOK in Q2 2021
InstitutionSharesValue% of portfolio
Octagon Capital Advisors LP296,822$9.99M2.07%
Balyasny Asset Management LLC64,805$2.18M0.01%
Alps Advisors Inc48,351$1.63M0.01%
Los Angeles Capital Management LLC17,117$576.0K0.00%
Principal Financial Group Inc8,365$282.0K0.00%
Invesco Ltd.8,002$269.0K0.00%
State Board of Administration of Florida Retirement System6,593$222.0K0.00%
XTX Topco Ltd6,422$216.0K0.07%
Amundi5,300$178.0K0.00%
Point72 Hong Kong Ltd1,363$46.0K0.00%
FFT Wealth Management LLC300$10.0K0.00%

Sold out (20)

Institutions that held Stoke Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.